From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas

IDH1 mutations induce organelle defects via dysregulated phospholipids

(2021) Adrian Lita et al.   Nature Communications

Amlexanox Enhances Temozolomide-Induced Antitumor Effects in Human Glioblastoma Cells by Inhibiting IKBKE and the Akt-mTOR Signaling Pathway

(2021) Jinbiao Xiong et al.   ACS Omega

A vaccine targeting mutant IDH1 in newly diagnosed glioma

(2021) Michael Platten et al.   NATURE

Meclofenamate causes loss of cellular tethering and decoupling of functional networks in glioblastoma

(2021) Matthias Schneider et al.   NEURO-ONCOLOGY

Patient-derived xenografts of different grade gliomas retain the heterogeneous histological and genetic features of human gliomas

(2020) Wenxin Zeng et al.   Cancer Cell International

EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma

(2020) Nina Struve et al.   ONCOGENE

Combined Delivery of Temozolomide and siPLK1 Using Targeted Nanoparticles to Enhance Temozolomide Sensitivity in Glioma

(2020) Hui Shi et al.   International Journal of Nanomedicine

Inhibition of Nrf2 might enhance the anti-tumor effect of temozolomide in glioma cells via inhibition of Ras/Raf/MEK signaling pathway

(2020) Wei Sun et al.   INTERNATIONAL JOURNAL OF NEUROSCIENCE

Phase 2 Study of a Temozolomide-Based Chemoradiation Therapy Regimen for High-Risk, Low-Grade Gliomas: Long-Term Results of Radiation Therapy Oncology Group 0424

(2020) Barbara J. Fisher et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Epigenetic preconditioning with decitabine sensitizes glioblastoma to temozolomide via induction of MLH1

(2020) Matthew Gallitto et al.   JOURNAL OF NEURO-ONCOLOGY

Mechanisms and therapeutic implications of hypermutation in gliomas

(2020) Mehdi Touat et al.   NATURE

Triptolide suppresses IDH1-mutated malignancy via Nrf2-driven glutathione metabolism

(2020) Di Yu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

mTORC2/Rac1 Pathway Predisposes Cancer Aggressiveness in IDH1-Mutated Glioma

(2020) Yang Liu et al.   Cancers

Identifying Predictive Gene Expression and Signature Related to Temozolomide Sensitivity of Glioblastomas

(2020) Hong-Qing Cai et al.   Frontiers in Oncology

Sirtuin activation targets IDH-mutant tumors

(2020) Julie J Miller et al.   NEURO-ONCOLOGY

Poly(ADP-ribose) glycohydrolase inhibition sequesters NAD+ to potentiate the metabolic lethality of alkylating chemotherapy in IDH mutant tumor cells

(2020) Hiroaki Nagashima et al.   Cancer Discovery

Large-Scale Drug Screening in Patient-Derived IDHmut Glioma Stem Cells Identifies Several Efficient Drugs among FDA-Approved Antineoplastic Agents

(2020) Philip Dao Trong et al.   Cells

Considering the Experimental Use of Temozolomide in Glioblastoma Research

(2020) Verena J. Herbener et al.   Biomedicines

Glutamate is a non-invasive metabolic biomarker of IDH1 mutant glioma response to temozolomide treatment

(2020) Elavarasan Subramani et al.   CANCER RESEARCH

Targeting isocitrate dehydrogenase mutations in cancer: emerging evidence and diverging strategies

(2020) Matthew S Waitkus et al.   CLINICAL CANCER RESEARCH

Glutamine reliance in cell metabolism

(2020) Hee Chan Yoo et al.   EXPERIMENTAL AND MOLECULAR MEDICINE

TERT and DNMT1 expression predict sensitivity to decitabine in gliomas

(2020) Jong-Whi Park et al.   NEURO-ONCOLOGY

PARP‑1 inhibition sensitizes temozolomide‑treated glioblastoma cell lines and decreases drug resistance independent of MGMT activity and PTEN proficiency

(2020) Ana Montaldi et al.   ONCOLOGY REPORTS

Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma

(2020) Lin Lin et al.   Cancer Research and Treatment

Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor

(2020) Yao Xiong et al.   NEOPLASIA

Sphingolipid Pathway as a Source of Vulnerability in IDH1mut Glioma

(2020) Tyrone Dowdy et al.   Cancers

Metabolic plasticity of IDH1-mutant glioma cell lines is responsible for low sensitivity to glutaminase inhibition

(2020) Victor Ruiz-Rodado et al.   Cancer & Metabolism

EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood

(2020) Michael Weller et al.   Nature Reviews Clinical Oncology

Revealing Temozolomide Resistance Mechanisms via Genome-Wide CRISPR Libraries

(2020) Clarissa Ribeiro Reily Rocha et al.   Cells

Temozolomide Induced Hypermutation in Glioma: Evolutionary Mechanisms and Therapeutic Opportunities

(2019) Paul Daniel et al.   Frontiers in Oncology

Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol

(2019) Paul Lesueur et al.   BMC CANCER

A phase Ib trial of CB-839 (telaglenastat) in combination with radiation therapy and temozolomide in patients with IDH-mutated diffuse astrocytoma and anaplastic astrocytoma (NCT03528642).

(2019) Sani Haider Kizilbash et al.   JOURNAL OF CLINICAL ONCOLOGY

Genome-Wide CRISPR-Cas9 Screens Expose Genetic Vulnerabilities and Mechanisms of Temozolomide Sensitivity in Glioblastoma Stem Cells

(2019) Graham MacLeod et al.   Cell Reports

Genomic correlates of disease progression and treatment response in prospectively characterized gliomas

(2019) Philip Jonsson et al.   CLINICAL CANCER RESEARCH

Inhibition of Gap Junctions Sensitizes Primary Glioblastoma Cells for Temozolomide

(2019) Anna-Laura Potthoff et al.   Cancers

Targeting of Histone Demethylases KDM5A and KDM6B Inhibits the Proliferation of Temozolomide-Resistant Glioblastoma Cells

(2019) Massimo Romani et al.   Cancers

Comprehensive Prognostic and Predictive Molecular Subgroup Analysis within the High-risk Treatment Arms of NRG Oncology/RTOG 9802: a Phase III Trial of RT versus RT + PCV in High-risk Low-grade Gliomas

(2019) E.H. Bell et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Inhibition of phosphatidylinositol 3-kinase by PX-866 suppresses temozolomide-induced autophagy and promotes apoptosis in glioblastoma cells

(2019) Bryan G. Harder et al.   MOLECULAR MEDICINE

Longitudinal molecular trajectories of diffuse glioma in adults

(2019) Floris P. Barthel et al.   NATURE

Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411)

(2019) Eric S. Schafer et al.   PEDIATRIC BLOOD & CANCER

PARP Inhibition in Cancer: An Update on Clinical Development

(2019) Esha Sachdev et al.   Targeted Oncology

Radiation and chemotherapy for high‐risk lower grade gliomas: Choosing between temozolomide and PCV

(2019) Susan G. R. McDuff et al.   Cancer Medicine

A Patient-Derived Glioblastoma Organoid Model and Biobank Recapitulates Inter- and Intra-tumoral Heterogeneity

(2019) Fadi Jacob et al.   CELL

2-Hydroxyglutarate-Mediated Autophagy of the Endoplasmic Reticulum Leads to an Unusual Downregulation of Phospholipid Biosynthesis in Mutant IDH1 Gliomas

(2018) Pavithra Viswanath et al.   CANCER RESEARCH

Procarbazine, lomustine and vincristine toxicity in low-grade gliomas

(2018) G. Jutras et al.   Current Oncology

IDH1-mutant cancer cells are sensitive to cisplatin and an IDH1-mutant inhibitor counteracts this sensitivity

(2018) Mohammed Khurshed et al.   FASEB JOURNAL

Reduced expression of DNA repair genes and chemosensitivity in 1p19q codeleted lower-grade gliomas

(2018) Lei Tang et al.   JOURNAL OF NEURO-ONCOLOGY

Temozolomide, sirolimus and chloroquine is a new therapeutic combination that synergizes to disrupt lysosomal function and cholesterol homeostasis in GBM cells

(2018) Sanford Hsu et al.   Oncotarget

Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma

(2018) Samuel K. McBrayer et al.   CELL

PLK1 inhibitor facilitates the suppressing effect of temozolomide on human brain glioma stem cells

(2018) Naijie Liu et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide

(2018) Alex Shimura Yamashita et al.   NEURO-ONCOLOGY

Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma

(2018) Shabierjiang JIAPAER et al.   NEUROLOGIA MEDICO-CHIRURGICA

ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenografts

(2018) Alice L. Yuan et al.   PLoS One

Lack of evidence for substrate channeling or flux between wildtype and mutant isocitrate dehydrogenase to produce the oncometabolite 2-hydroxyglutarate

(2018) Joseph P. Dexter et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Trehalose inhibits cell proliferation and amplifies long-term temozolomide- and radiation-induced cytotoxicity in melanoma cells: A role for autophagy and premature senescence

(2018) Giulia Allavena et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Low-Grade Glioma Radiotherapy Treatment and Trials

(2018) Tony J.C. Wang et al.   NEUROSURGERY CLINICS OF NORTH AMERICA

Pre-treatment or Post-treatment of Human Glioma Cells With BIX01294, the Inhibitor of Histone Methyltransferase G9a, Sensitizes Cells to Temozolomide

(2018) Iwona Anna Ciechomska et al.   Frontiers in Pharmacology

Targeting IDH1-Mutated Malignancies with NRF2 Blockade

(2018) Yang Liu et al.   JNCI-Journal of the National Cancer Institute

Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics

(2017) C. Izquierdo et al.   JOURNAL OF NEURO-ONCOLOGY

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study

(2017) Martin J van den Bent et al.   LANCET

Tumor microtubes convey resistance to surgical lesions and chemotherapy in gliomas

(2017) Sophie Weil et al.   NEURO-ONCOLOGY

Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02

(2017) Evanthia Galanis et al.   NEURO-ONCOLOGY

2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity

(2017) Parker L. Sulkowski et al.   Science Translational Medicine

Effect and molecular mechanism of mTOR inhibitor rapamycin on temozolomide‑induced autophagic death of U251 glioma cells

(2017) Bing Li et al.   Oncology Letters

Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL

(2017) Georg Karpel-Massler et al.   Nature Communications

IDH1 R132H mutation regulates glioma chemosensitivity through Nrf2 pathway

(2017) Kaishu Li et al.   Oncotarget

PLK1 inhibition enhances temozolomide efficacy in IDH1 mutant gliomas

(2017) Robert F. Koncar et al.   Oncotarget

Small molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cells

(2017) Barbara Banelli et al.   Oncotarget

Metformin and temozolomide, a synergic option to overcome resistance in glioblastoma multiforme models

(2017) Silvia Valtorta et al.   Oncotarget

Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1 -mutated or IDH2 -mutated solid tumours

(2017) Remco J Molenaar et al.   BMJ Open

Inhibitors of GLUT/SLC2A Enhance the Action of BCNU and Temozolomide against High-Grade Gliomas

(2017) Alberto Azzalin et al.   NEOPLASIA

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

(2016) David N. Louis et al.   ACTA NEUROPATHOLOGICA

The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide

(2016) Roy E. Strowd et al.   JOURNAL OF NEURO-ONCOLOGY

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

(2016) Brigitta G Baumert et al.   LANCET ONCOLOGY

Combine and conquer: challenges for targeted therapy combinations in early phase trials

(2016) Juanita S. Lopez et al.   Nature Reviews Clinical Oncology

Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide

(2016) Wolfgang Wick et al.   NEURO-ONCOLOGY

Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy forIDH1mutant glioma

(2016) Hiroaki Nagashima et al.   NEURO-ONCOLOGY

Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma

(2016) Jan C. Buckner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Polo-like kinase 1 mediates BRCA1 phosphorylation and recruitment at DNA double-strand breaks

(2016) Corinne Chabalier-Taste et al.   Oncotarget

Temozolomide toxicity operates in a xCT/SLC7a11 dependent manner and is fostered by ferroptosis

(2016) Tina Sehm et al.   Oncotarget

Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment

(2015) Hinke F. van Thuijl et al.   ACTA NEUROPATHOLOGICA

Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion

(2015) Kensuke Tateishi et al.   CANCER CELL

Minor Changes in Expression of the Mismatch Repair Protein MSH2 Exert a Major Impact on Glioblastoma Response to Temozolomide

(2015) J. L. McFaline-Figueroa et al.   CANCER RESEARCH

IDH1 Mutation Induces Reprogramming of Pyruvate Metabolism

(2015) J. L. Izquierdo-Garcia et al.   CANCER RESEARCH

Targeting homologous recombination, new pre-clinical and clinical therapeutic combinations inhibiting RAD51

(2015) Ambber Ward et al.   CANCER TREATMENT REVIEWS

A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma

(2015) Andra V. Krauze et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Combination of temozolomide and Taxol exerts a synergistic inhibitory effect on Taxol-resistant glioma cells via inhibition of glucose metabolism

(2015) DING-GUO GUAN et al.   Molecular Medicine Reports

Decitabine Nanoconjugate Sensitizes Human Glioblastoma Cells to Temozolomide

(2015) Yi Cui et al.   MOLECULAR PHARMACEUTICS

Brain tumour cells interconnect to a functional and resistant network

(2015) Matthias Osswald et al.   NATURE

Insulator dysfunction and oncogene activation in IDH mutant gliomas

(2015) William A. Flavahan et al.   NATURE

Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma

(2015) Patrick Y. Wen et al.   NEURO-ONCOLOGY

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas

(2015)   NEW ENGLAND JOURNAL OF MEDICINE

Erastin sensitizes glioblastoma cells to temozolomide by restraining xCT and cystathionine-γ-lyase function

(2015) LIANGYU CHEN et al.   ONCOLOGY REPORTS

A New Epigenetic Mechanism of Temozolomide Action in Glioma Cells

(2015) Anna-Maria Barciszewska et al.   PLoS One

DNA copy number analysis of Grade II–III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status

(2015) Adam Cohen et al.   Acta Neuropathologica Communications

Metabolic Reprogramming in Mutant IDH1 Glioma Cells

(2015) Jose L. Izquierdo-Garcia et al.   PLoS One

5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft

(2015) Alexandra Borodovsky et al.   Oncotarget

Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.

(2015) Sevin Turcan et al.   Oncotarget

Long-term Temozolomide Treatment Induces Marked Amino Metabolism Modifications and an Increase in TMZ Sensitivity in Hs683 Oligodendroglioma Cells

(2015) Delphine Lamoral-Theys et al.   NEOPLASIA

Long-term In Vitro Treatment of Human Glioblastoma Cells with Temozolomide Increases Resistance In Vivo through Up-regulation of GLUT Transporter and Aldo-Keto Reductase Enzyme AKR1C Expression

(2015) Benjamin Le Calvé et al.   NEOPLASIA

Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide)

(2014) Chang Xia et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Mutant IDH1-Driven Cellular Transformation Increases RAD51-Mediated Homologous Recombination and Temozolomide Resistance

(2014) Shigeo Ohba et al.   CANCER RESEARCH

Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in IDH-Mutant Gliomas

(2014) H. Wakimoto et al.   CLINICAL CANCER RESEARCH

A model of a patient-derived IDH1 mutant anaplastic astrocytoma with alternative lengthening of telomeres

(2014) Alexandra Borodovsky et al.   JOURNAL OF NEURO-ONCOLOGY

Asparagine Plays a Critical Role in Regulating Cellular Adaptation to Glutamine Depletion

(2014) Ji Zhang et al.   MOLECULAR CELL

An update on PARP inhibitors—moving to the adjuvant setting

(2014) Amir Sonnenblick et al.   Nature Reviews Clinical Oncology

Metformin—mode of action and clinical implications for diabetes and cancer

(2014) Ida Pernicova et al.   Nature Reviews Endocrinology

Chloroquine enhances temozolomide cytotoxicity in malignant gliomas by blocking autophagy

(2014) Encouse B. Golden et al.   Neurosurgical Focus

Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation

(2014) Fumiharu Ohka et al.   TUMOR BIOLOGY

Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation

(2014) Jinlong Shi et al.   TUMOR BIOLOGY

Unexpected low-dose toxicity of the universal solvent DMSO

(2013) Joana Galvao et al.   FASEB JOURNAL

Histone 3 Lysine 9 Trimethylation Is Differentially Associated With Isocitrate Dehydrogenase Mutations in Oligodendrogliomas and High-Grade Astrocytomas

(2013) Sriram Venneti et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Cerebral organoids model human brain development and microcephaly

(2013) Madeline A. Lancaster et al.   NATURE

Velocity of tumor spontaneous expansion predicts long-term outcomes for diffuse low-grade gliomas

(2013) Johan Pallud et al.   NEURO-ONCOLOGY

Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma

(2013) B. E. Johnson et al.   SCIENCE

A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth

(2013) Lei Wang et al.   Nature Communications

DNA hypermethylation and 1p Loss silence NHE-1 in oligodendroglioma

(2012) Michael D. Blough et al.   ANNALS OF NEUROLOGY

Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis

(2012) H. A. Tawbi et al.   ANNALS OF ONCOLOGY

Phase I Study of Vorinostat in Combination with Temozolomide in Patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03

(2012) E. Q. Lee et al.   CLINICAL CANCER RESEARCH

Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402

(2012) Gregory Cairncross et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951

(2012) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

Plk1 and CK2 Act in Concert to Regulate Rad51 during DNA Double Strand Break Repair

(2012) Keiko Yata et al.   MOLECULAR CELL

IDH mutation impairs histone demethylation and results in a block to cell differentiation

(2012) Chao Lu et al.   NATURE

Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation

(2012) Peppi Koivunen et al.   NATURE

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

(2012) Sevin Turcan et al.   NATURE

Magnetic Resonance of 2-Hydroxyglutarate in IDH1-Mutated Low-Grade Gliomas

(2012) A. Elkhaled et al.   Science Translational Medicine

Glioma cells showing IDH1 mutation cannot be propagated in standard cell culture conditions

(2011) S Piaskowski et al.   BRITISH JOURNAL OF CANCER

Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases

(2011) Wei Xu et al.   CANCER CELL

The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases

(2011) Rasheduzzaman Chowdhury et al.   EMBO REPORTS

Vorinostat modulates cell cycle regulatory proteins in glioma cells and human glioma slice cultures

(2011) Jihong Xu et al.   JOURNAL OF NEURO-ONCOLOGY

Valproic acid sensitizes human glioma cells for temozolomide and γ-radiation

(2011) Krista A. Van Nifterik et al.   JOURNAL OF NEURO-ONCOLOGY

A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study

(2011) Katherine E. Warren et al.   JOURNAL OF NEURO-ONCOLOGY

An in vivo patient-derived model of endogenous IDH1-mutant glioma

(2011) H. A. Luchman et al.   NEURO-ONCOLOGY

Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide

(2011) G. Prasad et al.   NEURO-ONCOLOGY

Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome

(2011) Z. J. Reitman et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Temozolomide: Mechanisms of Action, Repair and Resistance

(2011) Jihong Zhang et al.   Current Molecular Pharmacology

The prognostic IDH1 R132 mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma

(2010) Fonnet E. Bleeker et al.   ACTA NEUROPATHOLOGICA

Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma

(2010) Houtan Noushmehr et al.   CANCER CELL

Inhibition of Glutaminase Preferentially Slows Growth of Glioma Cells with Mutant IDH1

(2010) M. J. Seltzer et al.   CANCER RESEARCH

Oligodendroglioma cell lines containing t(1;19)(q10;p10)

(2010) J. J. P. Kelly et al.   NEURO-ONCOLOGY

The Neuropharmacokinetics of Temozolomide in Patients with Resectable Brain Tumors: Potential Implications for the Current Approach to Chemoradiation

(2009) J. Portnow et al.   CLINICAL CANCER RESEARCH

MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance

(2009) S. Yip et al.   CLINICAL CANCER RESEARCH

Development ofin vitrosystems for nanotoxicology: methodological considerations

(2009) Vicki Stone et al.   CRITICAL REVIEWS IN TOXICOLOGY

Phase II Trial of Temozolomide Plus O6-Benzylguanine in Adults With Recurrent, Temozolomide-Resistant Malignant Glioma

(2009) Jennifer A. Quinn et al.   JOURNAL OF CLINICAL ONCOLOGY

Knocking Down Galectin 1 in Human Hs683 Glioblastoma Cells Impairs Both Angiogenesis and Endoplasmic Reticulum Stress Responses

(2009) Marie Le Mercier et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

(2009) Lenny Dang et al.   NATURE

Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma

(2009) Jennifer A. Quinn et al.   NEURO-ONCOLOGY

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genomic Changes and Gene Expression Profiles Reveal That Established Glioma Cell Lines Are Poorly Representative of Primary Human Gliomas

(2008) A. Li et al.   MOLECULAR CANCER RESEARCH

Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts

(2008) Gaspar J. Kitange et al.   NEURO-ONCOLOGY

Mechanisms of Disease: temozolomide and glioblastoma—look to the future

(2008) Maciej M Mrugala et al.   Nature clinical practice. Oncology